WASHINGTON: US consumer prices jumped by the most in seven months in October, which together with abating fears of a recession, support the Federal Reserve’s signal for no further interest rate cuts in the near term.

The"...

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first, patient-centric strategy, diverse portfolio of approved medicines and its R&D engine is expected to drive the company’s near-term and sustained growth. In the near-term, Takeda expects that its 14 current global growth brands will generate significant momentum enabled by at least 20 additional indications and major market expansions through FY24. In the same time period, the organization anticipates delivering 12 new molecular entities with......

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whether in-hospital administration of empagliflozin 10 mg daily improves heart failure outcomes"...

As a leader in skincare innovation worldwide, Mary Kay Inc. continued its commitment to advance skin science as a symposium sponsor at the 44th annual meeting of The Japanese Society of Investigative Dermatology (JSID). At the conference held Nov. 8 - 10 in Aomori, Japan, the symposium"...

To raise awareness regarding matters surrounding men’s health and in observance of ‘Movember,’ an annual event involving the growing of moustaches all through the month of November, Fakih IVF Fertility Center has a special line-up of services rolled out for all its male"...

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (Takeda) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting. NINLARO is currently not approved......

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo) injection in patients with hereditary angioedema (HAE) 12 years of age and older studied in the ongoing Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE). The analyses, being presented at the 2019 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting in Houston, Texas from November 7-11, showed that TAKHZYRO continued to prevent HAE attacks at a rate similar to that observed......

− New England Journal of Medicine publishes primary endpoint analysis from ongoing Phase 3 study of Takeda’s dengue vaccine candidate

− Over 20,000 study participants in dengue-endemic areas in Latin America and Asia received two doses of Takeda’s dengue"...

Fakih IVF Fertility Center in Oman has recently witnessed an increase in number of patients battling infertility, over 800 patients have been treated since its inception. Doctors at the center suggest that the inability to conceive in certain cases is due to female factors and in many others"...

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003. The Singen vaccine plant will be utilized for formulation, fill, finish and secondary packaging of the dengue vaccine candidate starting with the packaging line. Takeda invested more than 130 million Euro and will employ up to 200 employees in the vaccine plant. According to the World Health Organization (WHO), dengue is the fastest spreading mosquito-borne viral disease, which is estimated to cause approximately 390 million infections and 20,000......